This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Main references
Anderson CC, Gabriel R: Poor hypotensive response and tachyphylaxis following intravenous labetalol. Cur Med Res Opin 5:424, 1978
Homeida M, Jackson L, Roberts CJC: Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J 2:1048, 1978
Martin LE, Hopkins R, Bland R: Metabolism of labetalol by animals and man. Br J Clin Pharmacol 3 (Suppl 3):695, 1976
McNeil JJ, Anderson AE, Louis WJ: Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol 8 (Suppl 2):157S, 1979
McNeil JJ, Louis WJ: Clinical pharmacokinetics of labetolol. Clin Pharmacokinet 9:157, 1984
Williams JG, De Voss K, Craswell PW: Labetalol in the treatment of hypertensive renal patients. Med J Aust 1:225, 1978
Wood AJ, Ferry DG, Bailey RR: Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol 13 (Suppl 1):81S, 1982
Main reference
Dengler HJ, Bodem G, Wirth K: Pharmakokinetische Untersuchungen mit H3-Digoxin und H3-Lanatosid beim Menschen. Arzneimittelforschung (Drug Res) 23:64: 1973
Main references
Aronoff GR, Sloan RS, Luft FC: Pharmacokinetics of moxalactam in patients with normal and impaired renal function. J Infect Dis 145:365, 1981
Aronoff GR, Sloan RS, Mong SA, Luft FC, Kleit SA: Moxalactam pharmacokinetics during hemodialysis. Antimicrob Agents Chemother 19:575, 1981
Donowitz GR, Mandell GL: Beta-lactam antibiotics (Second of two parts). N Engl J Med 318:490, 1988
Hoffman LH: Neurotoxicity associated with moxalactam. Clin Pharm 5:926, 1986
Jacobson EJ, Zahrowski JJ, Nissenson AR: Moxalactam kinetics in hemodialysis. Clin Pharmacol Ther 30:487, 1981
Jones TE, Milne RW, Mudaliar Y, Sansom LN: Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration. Antimicrob Agents Chemother 28:293, 1985
Lam M, Manion CV, Czerwinski AW: Pharmacokinetics of moxalactam in patients with renal insufficiency. Antimicrob Agents Chemother 19:461, 1981
Leroy A, Humbert G, Fillastre JP: Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother 19:965, 1981
Morse GD, Janicke D, Cafarell R, Piontek K, Apicella M, Jusko WJ, Walshe J: Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 38:150, 1985
Peterson LR, Bean B, Fasching CE et al.: Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects. Antimicrob Agents Chemother 20:378, 1981
Singlas E, Boutron HF, Merdjan H, Brocard JF, Pocheville M, Fries D: Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 34:403, 1983
Srinivasan S, Neu HC: Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis. Antimicrob Agents Chemother 20:398, 1981
Swanson DJ, Reitberg DP, Smit IL, Wels PB, Schentag JJ: Steady state moxalactam pharmacokinetics in patients: Non-compartmental versus two-compartmental analysis. J Pharmacokinet Biopharm 11:337, 1983
Main references
Di Carlo FJ, Leinweber FJ,; Szpiech JM, Davidson IWF: Metabolism of l-bunolol. Clin Pharmacol Ther 22:858, 1977
Leinweber JF, Greenough RC, Di Carlo FJ: Bunolol metabolism by dogs: Identification of basic metabolites and their conjugates. J Pharm Sci 66:1570, 1977
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:790, levobunolol hydrochloride
Main reference
Abrams WB, Coutinho CB, Leon AS, Spiegel HE: Absorption and metabolism of levodopa. JAMA 218:1912, 1971
Akpinar S: Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 39:739, 1982
Cedarbaum JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13:141, 1987
Doller HJ: Levodopa pharmacokinetics. Drug Metab Dispos 6:164, 1978
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1015, levodopa
Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharmacology 7:35, 1984
Oswald N, Keusch G, Binswanger U: Therapie der urämischen Sympathikopathie mit L-DOPA. Schweiz Med Wochenschr 107:1790, 1977
Sandyk R, Bernick C, Lee SM, Stern LZ, lacono RP, Bamford CR: L-DOPA in uremic patients with the restless legs syndrome. Int J Neurosci 35:233, 1987
von Scheele C: Levodopa in restless legs. Lancet II:426, 1986
Zech P, Collard M, Guey A, Plantier J, Bernard M, Berthoux F, Pinet A, Traeger J: Renal hemodynamic response to L-DOPA during acute renal failure in man. Biomedicine 23:456, 1975
Main references
Beckett GJ, Henderson CJ, Elwes R, Seth J, Lambie AT: Thyroid status in patients with chronic renal failure. Clin Nephrol 19:172, 1983
De Marchi S, Cacchin E: Alterations of circulating thyroid hormone levels in dialysis patients: Another piece to solve the puzzle. Nephron 46:400, 1987
Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH: Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med 316:764, 1987
Hoffman AS, Arem R, Eknoyan G: Thyroid function in renal failure. Semin Dialysis 1:154, 1988
Kaptein EM: Thyroid function in renal failure. Contrib Nephrol 50:64, 1986
Kerr DJ, Singh VK, Tsakiris D, McConnell H, Junor BJR, Alexander WD: Serum and peritoneal dialysate thyroid hormone levels in patients on continuous ambulatory peritoneal dialysis. Nephron 43:164, 1986
Lim VS, Zavala DC, Flanigan MJ, Freeman RM: Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients. Kidney Int 31:808, 1987
Löcsey L, Lenkey A, Leövey A: Hormonal changes in haemo-dialysed and in kidney-transplanted patients. Int Urol Nephrol 19:201, 1987
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1488, levothyroxine sodium.
Melmed S, Geola FL, Reed AW, Pekary AE, Park J, Hershman JM: A comparison of methods for assessing thyroid function in nonthyroidal illness. J Clin Endocrinol Metab 54:300, 1982
Pagliacci MC, Pelicci G, Grignani F, Giammartino C, Fedeli L, Carobi C, Buoncristiani U, Nicoletti I: Thyroid function tests in patients undergong maintenance dialysis: Characterization of the ‘Low-T4Syndrome’ in subjects on regular hemodialysis and continuous ambulatory peritoneal dialysis. Neprhon 46:225, 1987
Weissei M, Stummvoll HK, Kovarik J, Zimmermann E, Kaiser F, Fasching I, Puchegger R: Center-specific variations of thyroid hormone serum levels in hemodialysis patients. Nephron 44:212, 1986
Main references
Beckett AH, Boyes RN, Appleton PJ: The metabolism and excretion of lignocaine in man. J Pharm Pharmacol 18 (Suppl):76S, 1966
Benowitz NL, Meister W: Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 3:177, 1978
Blumer J, Strong JM, Atkinson JR jr: The convulsant potency of lidocaine and its N-dealkylated metabolites. J Pharmacol Exp Ther 186:31, 1973
Boyes RN, Scott DB, Jebson PJ et al.: Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 12:105, 1971
Breck GD, Trager WF: Oxidative N-dealkylation: A Mannich intermediate in the formation of a new metabolite of lidocaine in man. Science 173:544, 1971
Bromage PR, Gertel M: Brachial plexus anesthesia in chronic renal failure. Anesthesiology 36:488, 1972
Caille G, Lelorier J, Latour Y, Besner JG: GLC determination of lidocaine in human plasma. J Pharm Sci 66:1383, 1977
Collinsworth KA, Strong JM, Atkinson AJ jr, Winkle RA, Perlroth F, Harrison DC: Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharmacol Ther 18:59, 1975
DiFazio CA: Biotranformation of lidocaine. Int Anesthesiol Clin 13:21, 1975
Gibson TP, Nelson HA: Drug kinetics and artificial kidneys. Clin Pharmacokinet 2:403, 1977
Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA: Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31:350, 1982
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1217, lidocaine.
McNamara PJ, Slaughter RL, Pieper JA, Wyman MG, Lalka D: Factors influencing serum protein binding of lidocaine in humans. Anesth Analg 60:395, 1981
Pieper JA Slaughter RL, Anderson GD, Wyman MG, Lalka D: Lidocaine clinical pharmacokinetics. Drug Intell Clin Pharm 16:291, 1982
Rooke NT, Milne B: Acute pulmonary edema after regional anesthesia with lidocaine and epinephrine in a patient with chronic renal failure. Anesth Analg 63:363, 1984
Schuster SB, Kafer ER, Mandel S: Phrenic nerve block associated with interscalene brachial plexus block. Regional Anaesth 8:123, 1983
Strong JM, Mayfield DE, Atkinson AJ jr, Burris BC, Raymon F, Webster LT jr: Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide. Clin Pharmacol Ther 17:184, 1975
Tapia L, Cheigh JS, David DS, Sullivan JF, Saal S, Reidenberg MM, Stenzel KH, Rubin AL: Pruritus in dialysis patients treated with parenteral lidocaine. N Engl J Med 296:261, 1977
Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 78:499, 1973
Tucker GT, Boyes RN, Bridenbaugh PO, Moore DC: Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physiochemical properties, and anesthetic activity. Anesthesiology 33:287, 1970
Tucker GT, Mather LE: Properties, absorption, and disposition of local anesthetic agents. In: Cousins MJ (ed): Neural blockade in clinical anesthesia and management of pain; 2nd ed. Philadelphia: JB Lippincott, 1988 p 47
Vaziri ND, Saiki JK, Hughes W: Clearance of lidocaine by hemodialysis. South Med J 72:1567, 1979
Waller ES: Pharmacokinetic principles of lidocaine dosing in relation to disease state. J Clin Pharmacol 21:181, 1981
Main references
Janssen Pharmaceutica, Beerse (Belgium): Absorption, metabolism and excretion of orally administered lidoflazine in dogs. Biological Research Report R 7904/1, October 1970
Janssen Pharmaceutica, Beerse (Belgium): Absorption, metabolism and excretion of lidoflazine in man. Clinical Progress Report R 7904/15, March 1972
Janssen Pharmaceutica, Beerse (Belgium): The absorption, biotransformation and excretion of lidoflazine in man after a single oral dose of tritium-labelled drug. Clinical Research Report R 7904/83, August 1979
Janssen Pharmaceutica, Beerse (Belgium): The bioavailability of lidoflazine in healthy volunteers after oral administration of the drug at three dose levels (60, 120, 240 mg) and in three dosage forms. Clinical Report R 7904/85, September 1979
Janssen Pharmaceutica, Beerse (Belgium): Steady-state plasma levels of lidoflazine in patients treated with doses of 120 mg t.i.d. Clinical Research Report R 7904/86, October 1979
Janssen Pharmaceutica, Beerse (Belgium): The influence of a meal on the bioavailability of lidoflazine (R 7904) from a 120-mg tablet formulation in healthy volunteers. Clinical Research Report R 7904/87, August 1980
Janssen Pharmaceutica, Beerse (Belgium): Review of the pharmacokinetics and bioavailability of lidoflazine (R 7904) in man. Clinical Report R 7904/95, August 1983
Meuldermans W, Lauwers W, Knaeps A, Heykants J: In vitro metabolism of lidoflazine by rat and dog liver fractions. Arzneimittelforschung (Drug Res) 27(I):828, 1977
Main references
Malacoff RF, Finkelstein FO, Andriole VT: Effect of peritoneal dialysis on serum levels of tobramycin and lincomycin. Antimicrob Agents Chemother 8:574, 1975
Reinarz JA, Mcintosh DA: Lincomycin excretion in patients with normal renal function, severe azotemia and with hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother 5:232, 1965
Main references
Anagostou A, Miller M, Westenfelder C, Clemons G, Baranowski R: Effects of triiodothyronine replacement on the anemia of chronic renal failure. Exp Hematol 16:159, 1988
Beckett GJ, Henderson CJ, Elwes R, Seth J, Lambie AT: Thyroid status in patients with chronic renal failure. Clin Nephrol 19:172, 1983
De Marchi S, Cacchin E: Alterations of circulating thyroid hormone levels in dialysis patients: Another piece to solve the puzzle. Nephron 46:400, 1987
Hoffman AS, Arem R, Eknoyan G: Thyroid function in renal failure. Semin Dialysis 1:154, 1988
Kaptein EM: Thyroid function in renal failure. Contrib Nephrol 50:64, 1986
Kerr DJ, Singh VK, Tsakiris D, McConnell H, Junor BJR, Alexander WD: Serum and peritoneal dialysate thyroid hormone levels in patients on continuous ambulatory peritoneal dialysis. Neprhon 43:164, 1986
Lim VS, Flanigan MJ, Zavala DC, Freeman RM: Protective adaptation of low serum triiodothyronine in patients with chronic renal failure. Kidney Int 28:541, 1985
Lim VS, Zavala DC, Flanigan MJ, Freeman RM: Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients. Kidney Int 31:808, 1987
Löcsey L, Lenkey A, Leövey A: Hormonal changes in haemodialysed and in kidney-transplanted patients. Int Urol Nephrol 19:201. 1987
Melmed S, Geoela FL, Reed AW, Pekary AE, Park J, Hershman JM: A comparison of methods for assessing thyroid function in nonthyroidal illness. J Clin Endocrinol Metab 54:300, 1982
Weissel M, Stummvoll HK, Kovarik J, Zimmermann E, Kaiser F, Fasching I, Puchegger R: Center-specific variations of thyroid hormone serum levels in hemodialysis patients. Nephron 44:212, 1986
Main references
Beermann B: Pharmacokinetics of lisinopril. Am J Med 85 (Suppl 3B):25, 1988
Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR: Once-daily lisinopril in hypertensive patients effect on blood pressure and the renin-angiotensin system. Curr Ther Res 37:342, 1985
de Jong PE, Apperloo AJ, Heeg JE, de Zeeuw D: Lisinopril in hypertensive patients with renal function impairment. Neprhon 55 (Suppl 1):43, 1990
Gomez HJ, Cirillo VJ, Moncloa F: The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol 9 (Suppl 3):S27, 1987
Lancaster SG, Todd PA: Lisinopril. A preliminary review of the pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35:646, 1988
Rush JE, Merrill DD: The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 9 (Suppl 3):S99, 1987
Sneddon JM: MK-521, lysine analogue of enalapril. Drugs of the Future 8:925, 1983
Ulm EH, Michens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL: Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 14:357, 1982
Main references
Anonymous: Lithium in the management of mania and depression. Drug Ther Bull 8:97, 1970
Batlle D, Gaviria M, Grupp M, Arruda JAL, Wynn J, Kurtzman NA: Distal nephron function in patients receiving chronic lithium therapy. Kidney Int 21:477, 1982
Berens SC, Bernstein RS, Robbins J, Wolff J: Antithyroid effects of lithium. J Clin Invest 49:1357, 1970
Bucht G, Wahlin A, Wentzel T, Winblad B: Renal function and morphology in long-term lithium and combined lithium-neuroleptic treatment. Acta Med Scand 208:381, 1980
Burrows GD, Davies B, Kincaid-Smith P: Unique tubular lesions after lithium. Lancet 1:1310, 1978
Casper RC, Pandey G, Gosenfeld L, Davies JM: Intracellular lithium and clinical response. Lancet II:418, 1976
Depner TA: Nephrotic syndrome secondary to lithium therapy. Nephron 30:286, 1982
Dias N, Hocken AG: Oliguric renal failure complicating lithium carbonate therapy. Nephron 10:246, 1972
Hansen HE, Amdisen A: Lithium intoxication. Quart J Med 47:123, 1978
Harris CA, Jenner FA: The inhibition of the action of vasopressin by lithium ions. J Physiol (Lond) 200:59P, 1969
Hawkins JB, Dorken PR: Lithium. Lancet I:839, 1969
Hestbech J, Hansen HE, Amdisen A, Olsen S: Chronic renal lesions following long-term treatment with lithium. Kidney Int 12:205, 1977
Hestbech J, Aurell M: Lithium induced uremia. Lancet I:212, 1979
Jenner fA, Lee CR: Intracellular lithium and clinical response. Lancet II:641, 1976
Lavender S, Brown JN, Berrill WT: Acute renal failure and lithium intoxication. Postgrad Med J 49:277, 1973
Lee RV, Jampol LM, Brown WV: Nephrogenic diabetes insipidus and lithium intoxication: Complications of lithium carbonate therapy. N Engl J Med 284:93, 1971
Leonhardt KF: Pharmakodynamische Aspekte der Lithiumtherapie. Dtsch Med Wochenschr 99:174, 1974
Lydiard RB, Gelenberg AJ: Hazards and adverse effects of lithium. Annu Rev Med 33:327, 1982
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:365, lithium
Mellerup ET, Gronland H, Plenge P, Raffaelsen OJ: Effect of lithium on carbohydrate metabolism. J Psychosom Res 8:37, 1970
Murphy DL, Goodwin FK, Bunney WE: Aldosterone and sodium response to lithium administration in man. Lancet II:458, 1969
Myers JB, Morgan TO, Carney SL, Ray C: Effects of lithium on the kidney. Kidney Int 18:601, 1980
Peterson B, Shopsin B: Effect of lithium-choloride on the islets of Langerhans in guinea pigs. Acta Endocr (Copenh) 10:731, 1972
Port FK, Kroll PD, Rosenzweig J: Lithium therapy during maintenance hemodialysis. Psychosomatics 20:130, 1977
Procci WR: Mania during maintenance hemodialysis successfully treated with oral lithium carbonate. J Nerv Ment Dis 164:355, 1977
Radomski JL, Fuyat HN, Nelson A, Smith PK: Toxic effects, excretion and distribution of lithium chloride. J Pharmacol 100:429, 1950
Ramsey RA, Mendels J, Stokes JW, Fitzgerald RG: Lithium carbonate and kidney function. A failure in renal concentrating ability. JAMA 219:1446, 1972
Schou M: Lithium studies. I. Toxicity. Acta Pharmacol Toxicol (Copenh) 15:70, 1958
Schou M, Amdisen A, Trap-Jensen J: Lithium poisoning. Am J Psychiatry 125:520, 1968A
Schou M: Special review: Lithium in psychiatric therapy and prophylaxis. J Psychiat Res 6:67, 1968
Schou M: Die Lithium-Prophylaxe bei manisch-depressiven Psychosen. Nervenarzt 42:1, 1971
Scully RE, Galdabini JJ, McNealy BU: Weekly clinicopathological exercises. N Engl J Med 304:1025, 1981
Sedvall G, Johnson B, Petterson U, Levin K: Effects of lithium-salts on plasma-protein bound iodine and uptake of 131I in thyroid gland of man and rat. Life Sci 7:257, 1968
Singer I, Rotenberg D: Mechanism of lithium action. N Engl J Med 289:254, 1973
Thompson K: Serum-lithium determination for clinical use. Scand J Clin Lab Invest 20:104, 1967
Trautner EM, Morris R, Noack CH, Gershon J: The excretion and retention of ingested lithium and its effect on the ionic balance of man. Med J Aust 42:280, 1955
Tupin JP, Schlangenhauf GK, Creson DL: Lithium effects on electrolyte excretion. Am J Psychiatry 125:536, 1968
Walker RG, Bennett WM, Davies BM, Kincaid-Smith P: Structural and functional effects of long-term lithium therapy. Kidney Int 21 (Suppl 11):S13, 1982
Wallin L, Alling C, Aurell M: Impairment of renal function in patients on long-term lithium treatment. Clin Nephrol 18:23, 1982
Main references
Forshell GP, Siwers B, Tuck JR: Pharmacokinetics of lofepramine in man: Relationship to inhibitors of noradrenaline uptake. Eur J Clin Pharmacol 9:291, 1976
Main references
Ellis ME, Weiss RB, Kuperminc M: Nephrotoxicity of lomustine: A case report and literature review. Cancer Chemother Pharmacol 15:174, 1985
Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1247, chapter 55, Antiproliferative agents and drugs used for immunosuppression by P Calabresi and RE Parks
Harmon WE, Cohen JH, Schneeberger EE, Grupe WE: Chronic renal failure in children treated with methyl CCNU. N Engl J Med 300:1200, 1979
Micetich KC, Jensen-Akula M, Mandard JC et al.: Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. Am J Med 71:967, 1981
Oliverio VT: Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep 4:13, 1973
Schacht RG, Baldwin DS: Chronic interstitial nephritis and renal failure due to nitrosourea (NU) therapy. Kidney Int 14:661, 1978
Silver HKB, Morton DL: CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep 63:226, 1970
Main references General
Huber R: Research Report Byk Gulden, Konstanz (FRG), No. 331/1985
Riedel R: Pharmakologische Eigenschaften von Lonazolac-Ca, einer neuen antiphlogistisch und antirheumatisch wirkenden Substanz. Arzneimittelforschung (Drug Res) 31(I):655, 1981
Renal damage
Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984
Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985
Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984
Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980
Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984
Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987
Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982
Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986
Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980
Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980
Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982
Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986
Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxizität. Dtsch Med Wochenschr 110:469, 1985
Main references
Heykants JJP, Meuldermans WEG, Knaeps AG, Michiels LJM: The excretion and metabolism of the antidiarrhoeal loperamide in the wistar rat. Eur J Drug Metab Pharmacokinet 2:81, 1977
Shriver AD et al.: Loperamide. In: Goldberg ME (ed.): Pharmacological and biochemical properties of drug substances 3:461, 1981
Van Nueten JM, Janssen PAJ, Fontaine J: Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 3: In vitro studies on the peristaltic reflex and other experiments on isolated tissues. Arzneimittelforschung (Drug Res) 24:1641, 1974
Van Nueten JM, Helsen L, Michiels M, Heykants JJP: Distribution of loperamide in the intestinal wall. Biochem Pharmacol 28:1433, 1979
Weintraub HS, Killinger JM, Keykants J, Kanzler M, Jaff JH: Studies on the elimination rate of loper amide in man after administration of increasing oral doses of Imodium. Curr Ther Res 21:867, 1977
Main references
Illing HP, Bevan CD, Robinson JD, Chamberlain J, Fromson JM: Metabolism of loprazolam in rat, dog and man in vivo. Xenobotica 13:539, 1983
McInnes GT, Bunting EA, Ings RMJ, Robinson J, Ankier SI: Pharmacokinetics and pharmacodynamics following single and repeated nightly administrations of loprazolam, a new benzodiazepine hypnotic. Br J Clin Pharmacol 19:649, 1985
Stevens LA, Bevan CD, Salmon J, Krieger J, Perianu M, LeGo A: Single and repeated dose kinetics of the hypnotic agent loprazolam in healthy volunteers. Eur J Clin Pharmacol 25:651, 1983
Main references
Greenblatt DJ, Divoll M, Harmatz JS, Maclaughlin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 30:475, 1981
Morrison G, Chiang ST, Koepke HH, Walker BR: Effect of renal impairment and hemodialysis on lorazepam kinetics. Clin Pharmacol Ther 35:646, 1984
Verbeeck R, Tjandramaga TB, Verberckmoes R, De Schepper PJ: Biotransformation and excretion of lorazepam in patients with chronic renal failure. Br J Clin Pharmacol 3:1033, 1976
Main references
Amery WK, Heykants JJP, Xhonneux R, Towse G, Oettel P, Gough DA, Janssen PAJ: Lorcainide (R 15889), a first review. Acta Cardiol (Brux) 36:207, 1981
Eiriksson CE, Brogden RN: Lorcainide: A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27:279, 1984
Klotz U, Müller-Seydlitz P, Heimburg P: Pharmacokinetics of lorcainide in man: A new antiarrhythmic agent. Clin Pharmacokinet 3:407, 1978
Somani P: Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders. Am J Cardiol 48:157, 1981
Somani P, Simon V, Gupta RK, King P, Shapiro RS, Stockard H: Lorcainide kinetics and protein binding in patients with end-stage renal disease. Int J Clin Pharmacol Ther Toxicol 22:121, 1984
Main references
Hümpel M, Illi V, Milius W, Wendt H, Kurowski M: The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. Eur J Drug Metab Pharmacokinet 4:237, 1979
Hümpel M, IMieuweboer B, Milius W, Hanke H, Wendt H: Kinetics and biotransformation of lormetazepam. II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: First-pass effect. Clin Pharmacol Ther 28:673, 1980
Kampf D, Hümpel M, Lerche U, Kessel M: Effects of uremia and hemodialysis on lormetazepam disposition. Clin Pharmacol Ther 30:77, 1981
Main references
Tobert JA: New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76:534, 1987
Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160, 1988
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:749, loxapine
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1144, luteinising hormone
Main reference
Hümpel M, Wendt H, Dogs G, Weiß C, Rietz S, Speck U: Intraindividual comparison of pharmacokinetic parameters of d-norgestrel, lynestrenol and cyproterone acetate in 6 women. Contraception 16:199, 1977
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1137, lypressin
Main reference
Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1584, lysergide.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Seyffart, G. (1991). L. In: Drug Dosage in Renal Insufficiency. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3804-8_12
Download citation
DOI: https://doi.org/10.1007/978-94-011-3804-8_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5692-2
Online ISBN: 978-94-011-3804-8
eBook Packages: Springer Book Archive